Observational studyArtificial organs2026
Short Inter-Treatment Interval Treatment With Artificial Liver Support System Reduces 90-Day Transplant-Free Mortality in Patients With Hepatitis B Virus-Related Acute-On-Chronic Liver Failure: A Retrospective Observational Study.
Observational study in Artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimThis retrospective observational study aimed to compare the effects of short inter-treatment interval treatment (SIIT) versus long inter-treatment interval treatment (LIIT) using the artificial liver support system (ALSS) on liver function recovery and 90-day transplant-free mortality in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF).
methodsWe retrospectively analyzed 149 HBV-ACLF patients selected from 166 patients who received comprehensive internal medicine therapy combined with ALSS. Patients were categorized into the SIIT group and the LIIT group. Laboratory test data were recorded both before ALSS treatment and the seventh day after the last ALSS treatment. The 90-day transplant-free mortality was compared between the two groups.
resultsBiochemical indicators reflecting patient's liver function including alanine aminotransferase, aspartate aminotransferase, serum total bilirubin (TBIL), direct bilirubin (DBIL), total bile acid, and coagulation function (prothrombin time activity, PTA) were significantly improved at posttreatment than pretreatment in both groups (p < 0.05). At Day 7 after the last ALSS treatment, TBIL and DBIL levels were significantly lower in the SIIT group than in the LIIT group (p < 0.01). The 90-day transplant-free mortality in the SIIT group and LIIT group was 12.8% and 29.6%, respectively (p < 0.001). Higher baseline MELD score was associated with increased 90-day transplant-free mortality (OR = 1.815, 95% CI: 1.466-2.247, p < 0.001).
conclusionsIn patients with HBV-ACLF, SIIT with ALSS was associated with reduced 90-day transplant-free mortality compared with LIIT, although prospective studies are required to confirm causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.